Skip to main content

Defendant Fact Sheet Protocol Released For PPI Lawsuits

Defendant Fact Sheet Protocol Released For PPI Lawsuits

Defendant Fact Sheet Protocol Released For PPI Lawsuits

Introduction

In an order issued on July 30, the federal court overseeing the Proton Pump Inhibitor (PPI) litigation, established the form, procedure, and schedule for the completion and service of Defendant Fact Sheets (DFS).

The court announced that a completed Plaintiff Face Sheet (PFS) must be served by all the defendants either within 120 days from the date of the order's entry or within 120 days from the date on which the PFS is considered complete. If the PFS is served after July 30, the DFS must be served within 90 days from the date of PFS completion. Additionally, the order also states, any defendant can request via an email to the Plaintiffs' Counsel to get a 30 days extension to submit a completed DFS, which cannot be unreasonably withheld by the plaintiff.

The defendants involved in the litigation are AstraZeneca Pharmaceuticals LP, Procter & Gamble Co., McKesson Corp., Takeda Pharmaceuticals USA Inc., Novartis Pharmaceuticals Corp., and Pfizer Inc.

More than 4,700 lawsuits are filed by individuals claiming the PPI manufacturers failed to warn them about kidney failure and other renal complications due to the long-term use of Nexium, Prilosec, PrevAcid, Protonix, or Dexilant. PPI lawsuits were centralized on August 2, 2017, as a part of the multidistrict litigation (MDL No. 2789; In Re: Proton-Pump Inhibitor Products Liability Litigation [No. II]) overlooked by Judge Claire C. Cecchi in the District of New Jersey.

Comments

Restricted HTML

  • Allowed HTML tags: <a href hreflang> <em> <strong> <cite> <blockquote cite> <code> <ul type> <ol start type> <li> <dl> <dt> <dd> <h2 id> <h3 id> <h4 id> <h5 id> <h6 id>
  • Lines and paragraphs break automatically.
  • Web page addresses and email addresses turn into links automatically.

Latest News

Study Links Roundup Chemical to Long-Term Brain Damage

Categories: Roundup

A recent study suggests that exposure to the widely used herbicide Roundup, which contains the active ingredient glyphosate, may be…

Zimmer Biomet Gets FDA Approval for Cementless Partial Knee

Zimmer Biomet announced it has received supplemental FDA premarket approval (PMA) for the Oxford Cementless Partial…

Court Names Special Masters for Bard Mesh Claim Settlements

Categories: Hernia Mesh

The U.S. District Judge overseeing the federal litigation involving Bard hernia mesh lawsuits has appointed two…

Demand Letter or Medical Record Review?     
Free Trials + 10% Discount!